|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||||||||||||
  HIV MedicineVolume 7 Issue 5, Pages 338 - 344 Published Online: 24 May 2006 © 2010 British HIV Association
Abstract | References | Full Text: HTML, PDF (Size: 106K) | Related Articles | Citation Tracking  ORIGINAL RESEARCH Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women Copyright © 2006 British HIV Association KEYWORDS hepatotoxicity • HIV mother-to-child transmission • nevirapine-containing regimen • public health • resource-limited settings Objective
To assess the incidence and consequences of adverse reactions among African HIV-positive pregnant women treated with fixed-dose combinations of a nevirapine-containing antiretroviral (ARV) triple therapy. MethodsA retrospective analysis of the clinical files of 703 HIV-1-positive pregnant women treated with a nevirapine-containing regimen between May 2002 and July 2004 was conducted. Selection criteria for inclusion in the analysis were: (a) taking ARV for more than 14 days; (b) baseline values of transaminases below the threshold of 2.5 times the upper limit of normal (ULN). The women were on a nevirapine-containing regimen for a median of 127 days [interquartile range (IQR) 86–190 days], starting on average at the 27th week of gestation (standard deviation±9.5) and continuing up to a maximum of 6 months after delivery. All women were offered formula milk to feed the babies. Highly active antiretroviral therapy (HAART) was continued beyond 6 months only if the patient qualified on the first visit. The main outcome measures were incidence of hepatotoxicity, skin rashes and Stevens–Johnson syndrome. Multivariate analysis to assess the impact of several factors on the adverse reaction rate was performed. ResultsAs of 1 August 2004, 554 pregnancies reached term, 96 women were still pregnant, and 53 women dropped out of the programme before giving birth. After 2 months of therapy the percentage of patients with a viral load less than 1000 HIV-1 RNA copies/mL increased to 78.6%; average CD4 cell counts increased from 490 cells/μL before therapy to 630 after therapy. The incidence of grade 3–4 adverse reactions (hepatotoxicity, skin rashes and Stevens–Johnson syndrome) was 6.5, 2.4 and 1.1%, respectively. Five women died during pregnancy (0.88%). Only one of the deaths could be associated with ARV treatment. ConclusionNevirapine-containing regimens in pregnant woman, at all CD4 cell count levels, appear to be safe in African settings. Received: 7 July 2005, accepted 28 November 2005 | 
|
| ||||||||||||||||
|
||||||||||||||||||
|
